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Deamidation of asparaginyl and glutaminyl residues causes time-
dependent changes in charge and conformation of peptides and
proteins. Quantitative and experimentally verified predictive cal-
culations of the deamidation rates of 1,371 asparaginyl residues in
a representative collection of 126 human proteins have been
performed. These rates suggest that deamidation is a biologically
relevant phenomenon in a remarkably large percentage of human
proteins.
in vivo deamidation u asparaginyl residues
Deamidation of asparaginyl (Asn) and glutaminyl (Gln)residues to produce aspartyl (Asp) and glutamyl (Glu)
residues causes structurally and biologically important alter-
ations in peptide and protein structures. At neutral pH, deami-
dation introduces a negative charge at the reaction site and can
also lead to structural isomerization. Early work established that
deamidation occurs in vitro and in vivo, and that the rates of
deamidation depend on primary sequence, three-dimensional
(3D) structure, pH, temperature, ionic strength, buffer ions, and
other solution properties (1–11). It has been hypothesized (3, 5,
7, 12, 13) that Asn and Gln may serve, through deamidation, as
molecular clocks which time biological processes such as protein
turnover, homeostatic control, and organismic development and
aging, as well as mediators of postsynthetic production of new
proteins of unique biological value.
Deamidation has been observed and characterized in a wide
variety of proteins. It has been shown to regulate some time-
dependent biological processes (8, 9) and to correlate with
others, such as development and aging. There are many reports
of deamidation under physiological conditions in proteins of
biological significance. For examples, see refs. 14–18.
Extensive evidence suggests that deamidation of Asn at neu-
tral pH usually proceeds through a cyclic imide reaction mech-
anism (19–21). Sometimes the Asp produced by deamidation is
isomerized to isoAsp. The in vivo reversal of this isomerization
has been widely reported, but reversal of deamidation itself and
of the introduced negative charge has not been observed.
Deamidation rates depend on the amino acid residues near
Asn and Gln in the peptide chain with sequence-determined
deamidation half-times at neutral pHs and 37°C in the range of
1–500 days for Asn and 100–.5,000 days for Gln (7, 13).
Sequence-determined Asn and Gln deamidation rates are
modulated by peptide and protein 3D structures. Deamidation
of peptides is observed at both Asn and Gln, largely in accor-
dance with sequence-controlled rates. Deamidation of proteins,
which is usually slowed by 3D structure, occurs primarily at Asn
except in very long-lived proteins where Gln deamidation is also
observed. In a few instances, 3D structure has been reported to
increase deamidation rate.
The deamidation rates of individual Asn residues in a protein
can be reliably predicted as a result of two recent advances. First,
the sequence-controlled Asn deamidation rates of most of the
400 possible near-neighbor combinations in pentapeptide mod-
els have been measured (13), and the relevance of this rate
library has been established (22). Second, these rates and the 3D
structures of proteins with well characterized deamidations have
been combined to produce a computation method that correctly
predicts the deamidation rates of most Asn residues for which the
3D structure is known (23). This method is more than 95%
reliable in predicting relative deamidation rates of Asn residues
within a single protein and is also useful for the prediction of
absolute deamidation rates.
It is, therefore, now possible to compute the expected deami-
dation rate of any protein for which the primary and 3D
structures are known, except for very long-lived proteins. These
proteins require measurement of the 400 Gln pentapeptide rates.
Materials and Methods
Calculation Method. The Brookhaven Protein Data Bank (PDB)
was searched to select 126 human proteins of general biochem-
ical interest and of known 3D structure without bias toward any
known data about their deamidation, except for 13 proteins (as
noted in Table 1) where deamidation has been measured.
The deamidation half-time of each of the 126 proteins was
obtained by first computing the deamidation coefficients (CD) of
each Asn and then combining these values into the deamidation
index (ID) by the methods reported (23).
The deamidation coefficient, CD, is defined as CD 5
(0.01)(t1/2)(ef(Cm,CSn,Sn)), where t1/2 is the pentapeptide primary
structure half-life (13), Cm is a structure proportionality factor,
CSn is the 3D structure coefficient for the nth structure obser-
vation, Sn is that observation, and f (Cm,CSn,Sn) 5 Cm[(CS1)(S1)
1 (CS2)(S2) 1 (CS3)(S3) 2 (CS4,5)(S4)y(S5) 1 (CS6)(S6) 1
(CS7)(S7) 1 (CS8)(S8) 1 (CS9)(S9) 1 (CS10)(1 2 S10) 1 (CS11)(5 2
S11) 1 (CS12)(5 2 S12)]. The structure observations, Sn, are those
that impede deamidation, including hydrogen bonds, a-helices,
b-sheets, and peptide inflexibilities.
For Asn in an a-helical region:
S1 5 distance in residues inside the a-helix from the NH2 end,
where S1 5 1 designates the end residue in the helix, 2 is
the second residue, and 3 is the third. If the position is 4 or
greater, S1 5 0.
S2 5 distance in residues inside the a-helix from the COOH end,
where S1 5 1 designates the end residue in the helix, 2 is
the second residue, and 3 is the third. If the position is 4 or
greater or S1 Þ 0, then S2 5 0.
S3 5 1 if Asn is designated as completely inside the a-helix
because it is 4 or more residues from both ends. If the Asn
is completely inside, S3 5 1, S1 5 0, and S2 5 0. If S1 Þ 0
or S2 Þ 0, then S3 5 0.
For flexibility of a loop including Asn between two adjacent
antiparallel b-sheets:
S4 5 number of residues in the loop.
S5 5 number of hydrogen bonds in the loop. S5 $ 1 by definition.
For hydrogen bonds:
S6 5 the number of hydrogen bonds to the Asn side chain C5O
group. Acceptable values are 0, 1, and 2.
Abbreviation: 3D, three-dimensional.
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Uracil-DNA glycosylase (1LAU) 1.0 0.15 Proinsulin (1EFE) 110 17
Uroporphyrinogen decarboxylase (1URO) 1.0 0.15 Mitogen-activated protein kinase P38 (1WFC) 110 17
Transaldolase (1F05) 1.4 0.21 Glutathione reductase (1BWC) 120 18
Urokinase-type plasminogen activator (1LMW) 1.7 0.26 Ribonuclease 4 (1RNF) 130 20
Purine nucleoside phosphorylase (1ULA) 1.8 0.27 Aldose reductase (1EL3) 130 20
Growth hormone receptor (1A22) 2.4 0.36 a-Lactalbumin (1B9O) 130 20
Peptidyl-prolyl cis-trans isomerase (1F8A) 2.4 0.36 Ornithine transcarbamoylase (1OTH) 130 20
Thymidylate synthase (1HW3) 2.7 0.41 Malic enzyme (1EFK) 140 21
Procathepsin B (3PBH) 2.9 0.44 Glucose-6-phosphate 1-dehydrogenase (1QKI) 140 21
D-Glyceraldehyde-3-phosphate dehydrogenase (3GPD) 4.2 0.64 Procarboxypeptidase A2 (1AYE) 150 23
Karyopherin b2 (1QBK) 5.3 0.81 Apoptosis regulator bax (1F16) 170 26
Glutathione S-transferase (12GS) 5.3 0.81 Ornithine decarboxylase (1D7K) 170 26
N-acetylgalactosamine-4-sulfatase (1FSU) 6.1 0.93 UDP-galactose 4-epimerase (1EK6) 180 27
Fructose bisphosphate aldolase (4ALD) 7.6 1.2 Stem cell factor (1EXZ)* 180 27
Intestinal fatty acid binding protein (3IFB) 7.6 1.2 Hypoxanthine guanine phosphoribosyltransferase (1BZY)* 180 27
Cyclophilin A (1AWQ) 8.7 1.3 Electron transfer flavoprotein (1EFV) 190 29
Vascular endothelial growth factor (2VPF)* 10 1.5 Phenylalanine hydroxylase (1DMW) 220 33
Inositol monophosphatase (1IMB) 15 2.3 Annexin V (1ANX) 220 33
Pancreatic inhibitor variant 3 (1CGI) 16 2.4 Platelet factor 4-HPF4 (1RHP) 230 35
D-Glucose 6-phosphotransferase (1HKC) 16 2.4 Insulin (2HIU)* 260 40
Myeloperoxidase (1MHL) 16 2.4 Prethrombin2 (1HAG) 260 40
a-Chymotrypsinogen (1CGI) 16 2.4 Interleukin-4 (2CYK) 270 41
Lysophospholipase (1LCL) 16 2.4 Interleukin-1b (2I1B) 280 43
Interleukin-16 (1I16) 17 2.6 Neutrophil (gelatinase) (1DFV) 290 44
C-AMP-dependent kinase A (1CMK) 19 2.9 O6-alkylguanine-DNA alkyltransferase (1EH6) 300 46
Pepsinogen (1HTR) 20 3.0 Glucosamine-6-phosphate deaminase isomerase (1D9T) 320 49
Angiogenin (1A4Y)* 21 3.2 Quinone reductase type 2 (1QR2) 330 50
Fibroblast growth factor (2AFG)* 21 3.2 Nad(P)H dehydrogenase (1QBG) 350 53
Gastric lipase (1HLG) 21 3.2 Serum albumin (1E7G) 360 55
Calmodulin (1CTR) 21 3.2 Plasminogen activator inhibitor-1 (1C5G) 370 56
Bone morphogenetic protein 7 (1BMP) 21 3.2 T cell surface glycoprotein CD4 (1CDJ)* 380 58
Acetylcholinesterase (1F8U) 23 3.5 a-Thrombin (1A3E) 380 58
Retinol binding protein (1BRQ)* 24 3.6 Eosinophil cationic protein (1QMT) 430 65
Catalase (1QQW) 25 3.8 Ribonuclease inhibitor (1A4Y) 450 68
Dihydrofolate reductase (1DRF) 25 3.8 Transforming growth factor-b two (1KLA) 460 70
Interleukin-10 (2ILK) 25 3.8 Thioltransferase (1JHB)* 470 71
Farnesyltransferase (1EZF) 26 4.0 Profilin 1 (1FIL) 480 73
S-adenosylhomocysteine hydrolase (1A7A) 28 4.3 Lithostathine (1LIT) 490 74
Procathepsin K (1BY8) 28 4.3 Phosphatidylethanolamine binding protein (1BD9) 680 100
3-Methyladenine DNA glycosylase (1BNK) 35 5.3 Dihydroorotate dehydrogenase (1D3G) 720 110
Medium chain acyl-coa dehydrogenase (1EGE) 36 5.5 Quinone reductase (1D4A) 750 110
Homeobox protein PAX-6 (6PAX) 39 5.9 Hemoglobin (1A3N)* 780 120
a1-Antitrypsin (1QLP) 40 6.1 Retinoic acid receptor (1BY4) 860 130
Carbonic anhydrase I (1HCB) 45 6.8 Psoriasin (1PSR) 890 140
GTP-binding protein (1DOA) 45 6.8 ADP-ribosylation factor 6 (1E0S) .1000 150
Ferritin (2FHA) 46 7.0 Lectin L-14-II (1HLC) .1000 180
Procathepsin L (1CS8) 48 7.3 Nucleoside diphosphate kinase (1NUE) .1000 210
Growth hormone (1HGU)* 51 7.8 L-3-Hydroxyacyl-CoA dehydrogenase (1F0Y) .1000 230
Triose phosphate isomerase (1HTI)* 52 7.9 Interleukin 2 (3INK)* .1000 230
Interleukin-6 (1IL6) 56 8.5 Transthyretin (1DVQ) .1000 290
DNA polymerase b (1BPX) 58 8.8 Single-stranded DNA binding protein (3ULL) .1000 290
Glutathione synthetase (2HGS) 58 8.8 Protein kinase C interacting protein 1 (1KPA) .1000 300
Fructose-1,6-bisphosphatase (1FTA) 59 9.0 GTPase ran (1QBK) .1000 380
CDK2 kinase (1BUH) 65 9.9 Annexin III (1AXN) .1000 430
Ribonuclease A (1AFK) 66 10 Fk506-binding protein (1D6O) .1000 710
Ap endonuclease (1BIX) 72 11 Interleukin-5 (1HUL) .1000 760
Carbonic anhydrase IV (1ZNC) 72 11 Heme oxygenase (1QQ8) .1000 780
Branched-chain a-keto acid dehydrogenase (1DTW) 81 12 Histone H2A.Z (1F66) .1000 .1000
Argininosuccinate lyase (1AOS) 83 13 Copper transport protein ATOX1 (1FEE) .1000 .1000
Creatine kinase (1QK1) 84 13 17 b-Hydroxysteroid dehydrogenase (1DHT) .1000 .1000
Carbonic anhydrase II (1BV3) 90 14 Myoglobin (2MM1) .1000 .1000
Interleukin-8 (1IL8) 95 14 Ubiquitin (1D3Z) .1000 .1000
Dihydropteridine reductase (1HDR) 100 15 Granulocyte colony-stimulating factor (1RHG) .1000 .1000
The proteins were selected without regard to reported deamidation except for 13 proteins that were among those used to develop and test the calculation
method (23, 26–28) and are designated with an asterisk in the table.
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S7 5 the number of hydrogen bonds to the Asn side chain NH2
group. Acceptable values are 0, 1, and 2.
S8 5 the number of hydrogen bonds to the backbone N in the
peptide bond on the COOH side of Asn. Hydrogen bonds
counted in S6 or S7 are not included. Acceptable values are
0 and 1. This nitrogen is used in the five-membered
succinimide ring.
S9 5 additional hydrogen bonds, not included in S6, S7, and S8,
that would need to be broken to form the succinimide ring.
For Asn situated so that no a-helix, b-sheet, or disulfide bridge
structure is between the Asn and the end of the peptide chain:
S10 5 1 if the number of residues between the Asn and the
nearest such structure is 3 or more. If the number of
intervening residues is 2, 1, or 0, or if the Asn is not
between structure and chain end, then S10 5 0.
If the Asn lies near to any a-helix, b-sheet, or disulfide bridge
structures:
S11 5 the number of residues between the Asn and the structure
on the NH2 side, up to a maximum of 5. Values of 0, 1, 2,
3, 4, and 5 are acceptable.
S12 5 the number of residues between the Asn and the structure
on the COOH side, up to a maximum of 5. Values of 0, 1,
2, 3, 4, and 5 are acceptable.
Hydrogen bonds are accepted if the bond length is 3.3 Å or less
and there is room in the structure to accommodate the van der
Waals radius of the hydrogen. All primary structure t1/2 values
are those published (13), except for Asn with carboxyl-side Pro,
Asn, or Gln, and Asn without a free amide as a result of binding
to metals or other moieties. Estimated values of t1/2 of 500, 40,
60, and 500 days are used for AsnPro, AsnAsn, AsnGln, and
bound Asn, respectively.
The coefficients Cm and CSn were optimized by means of the
DP method (23–25) with an increased set of proteins (26–29). DP
is a measure of the percentage accuracy in classifying the relative
deamidation rates of Asn residues in a set of proteins (23).
Proteins added to the original set (23) and their Protein Data
Bank numbers were bovine DNase I (2DNJ), human hirudin
(4HTC), bovine calmodulin (1A29), and human vascular endo-
thelial growth factor (2VPF). Human T cell surface glycoprotein
CD4 (1CDJ) was omitted. The Asn 3D environments in all 31 of
the calibration proteins were examined and retabulated. These
31 proteins include all of the proteins suitable for this purpose
that we have found in the research literature.
The optimized values were Cm 5 0.48, CS1 5 1.0, CS2 5 2.5,
CS3 5 10.0, CS4,5 5 0.5, CS6 5 1.0, CS7 5 1.0, CS8 5 3.0, CS9 5
2.0, CS10 5 2.0, CS11 5 0.2, and CS12 5 0.7. These values are
identical to those found in ref. 23. The deamidation resolving
power (DP) was found to be 95.4%.
The protein deamidation index is defined as ID 5 [S
(CDn)21]21, where CDn is CD for the nth Asn residue. Therefore,
(100)(ID) is an estimate of the initial single-residue deamidation
half-time for the protein with all Asn residues considered.
Comparison of Calculated Rates with Experimental Rates
The Medline and Citation Index databases were searched for all
proteins in which the deamidation rates of identified Asn
residues have been reported for 37°C solutions with pH at or
near 7.4. Reports were found for a total of 10 individual Asn and
3 combinations of Asn residues in 10 different protein types (17,
18, 23, 29–35). These include 7 proteins that are in the human
set of 126 and 3 proteins from other species.
The names, Protein Data Bank numbers, Asn residue position,
and computed (100)(ID) values, respectively, for these proteins
are rabbit aldolase: 1ADO, 360, 8.3; human vascular endothelial
growth factor: 2VPF, 10, 10; Escherichia coli Hpr-phosphocar-
rier protein: 1HDN, 12–38, 89–22; human fibroblast growth
factor: 2AFG, 7, 64; human angiogenin: 1B1I, All, 28; human
retinal binding protein: 1BRQ, All, 29; human growth hormone
(GH): 1HGU, All, 51; human triose phosphate isomerase: 1HTI,
71, 78; bovine ribonuclease A: 1AFK, 67, 84; and human
hemoglobin: 1A3N, with Asn mutants at a50-b80-b82,
47-190-184.
Fig. 1 compares the computed half-times for pH 7.4, 37°C, 0.15
M TriszHCl buffer with the experimentally observed (17, 18,
29–35) values. The computed values compare favorably with the
Fig. 1. Calculated single deamidation half-times for 10 individual Asn and 3
combinations of Asn residues in 10 different protein types vs. the correspond-
ing experimentally observed deamidation half-times (17, 18, 23, 29–35).
Experiments were in vitro in Tris and phosphate buffers and in vivo in human
blood. Buffer conditions in Tris and phosphate varied among these investi-
gations but were comparable to pH 7.4, 37°C, 0.15 M. Some of the scatter in
the figure is probably the result of these variations. If the calculated values and
experimental values were identical, the points would lie on the solid black line,
as do the values determined in Tris buffers. Catalysis of deamidation is higher
by phosphate than by Tris and may be even higher in erythrocytes.








experimental values in Tris buffer. In phosphate buffer, the
experimental deamidation rates are, on average, 2-fold higher
than calculated, and the 3 in vivo human blood values average
3-fold higher. This result is entirely as expected because deami-
dation at neutral pH is subject to catalysis by solution ions. Tris
is a very mild catalyst of deamidation. Phosphate is a much
stronger catalyst of deamidation in peptides (6, 11) and proteins
(17) as compared with Tris. Tissue culture medium contains
components even more catalytic of deamidation than phosphate
(36). Least-squares lines as shown in Fig. 1 give experimental
deamidation rates relative to the computed values in Tris,
phosphate, and in vivo blood erythrocytes of 1.06, 2.07, and 3.01,
respectively.
The agreement between the calculated values and Tris exper-
imental values in Fig. 1 does not arise from computational
forcing. The computational method (23) uses experimental
sequence-determined pentapeptide deamidation rates in Tris
buffer and a parametric 3D structure function with adjustable
constants. The optimization method (23–25) for these constants
used only the ordered Asn residue instabilities in a wide variety
of proteins and buffer types. No experimental absolute deami-
dation rates were used. The agreement arises because the
computational method correctly estimates the relative primary
and 3D contributions to the deamidation rate of each Asn, and
the primary rates were experimentally determined in Tris.
Results and Discussion
Averaged over all 1,371 Asn, the contributions to the deamida-
tion reaction activation energy from primary and 3D structures
are about equal, although they vary widely for individual Asn
residues. The average relative deamidation rates of Asn within
single proteins in this 126-protein set are 60% determined by
primary and 40% by 3D structure, which are the same propor-
tions found for a different 24-protein set (23). The cumulative
distribution function of the calculated first-order rate constants
for deamidation of the 1,371 Asn residues is shown in Fig. 2a.
The computed single deamidation half-times in pH 7.4, 37°C,
0.15 M TriszHCl buffer for the 126 human proteins are shown in
Table 1. Table 2 summarizes, on the basis of Table 1, the extent
to which deamidation is expected to occur within this set of 126
proteins.
The percentages of deamidation in living tissues are probably
higher than shown in Tables 1 and 2. Physiological f luids contain
many inorganic, organic, and biochemical substances with de-
amidase activity. We know of no reported instance, in vivo or in
vitro, of an experimentally measured protein deamidation rate
that is slower than its computed Tris rate. All reported rates are
the same or faster. There are two instances of individual proteins
(13, 23) in which negative results for the detection of deamida-
tion in specific amides indicates that the rates, if measured, might
be slower than calculated.
This deamidation is not a random consequence of the pres-
ence of Asn residues in proteins. The fast deamidations sum-
marized in Table 2 result from a set of Asn residues with unusual
primary and 3D structures, which comprise about 5% of the
total. As illustrated in Fig. 2, most individual Asn deamidation
rates are slower. Because a large number of similarly sized
partially independent factors determine Asn deamidation rates
in proteins, the distribution functions in Fig. 2 would be expected
to be Gaussian. Fig. 2b shows the deviation from Gaussian
caused by the unusual Asn residues.
Conclusions
The unstable Asn residues that give rise to the deamidation rates
shown in Tables 1 and 2 and Figs. 1 and 2 are apparently
preferred over the many stable Asn residues that could easily be
genetically specified. As shown in Fig. 2, most Asn residues are
far more stable. Moreover, even if it were not a result of
preference, this introduction of negative charges into protein
structures would do unacceptable biochemical damage unless it
was being used for compensating biological purposes.
Although postsynthetic deamidated proteins are often ob-
served in tissue extracts, their production can be obscured. For
example, the in vivo steady-state concentrations of the deami-
dated forms of cytochrome c are much lower than expected
Fig. 2. (a) Cumulative distribution function of the calculated first-order rate
constants for deamidation of 1,371 Asn residues in 126 human proteins. As
indicated, the Asn residues involved in the initial deamidation of these pro-
teins comprise a relatively small part of the complete set. Computed percent-
ages of the Asn residues that are 1y10 deamidated at 1 and 10 days in Tris are
1% and 4%, respectively, as shown. If this deamidation were not of positive
biological value, more slowly deamidating sequences and 3D structures could
easily have been used. (b) Differentiated values of the distribution function in
a showing the special class of unstable Asn residues present in human proteins.
Also shown is a Gaussian function that fits the distribution function except for
that part arising from the especially unstable Asn residues. The shaded area
contains those Asn residues computed to be one-tenth or more deamidated in
10 days in pH 7.4, 37°C, 0.15 M TriszHCl. This shaded area for phosphate,
physiological fluids, or longer time intervals would be a larger part of the
illustrated deviation from Gaussian.
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because they are preferentially degraded (7, 8). Those deami-
dated forms that are not degraded and, therefore, accumulate in
living tissues may have other unique biological purposes. Oth-
erwise, their accumulation would be disadvantageous.
Moreover, the deamidation rates in living tissues are change-
able. Through the production of enzymatic deamidases or the
control of other physiological parameters that affect the reaction
activation energy of deamidation, a living cell could easily
increase the overall deamidation rates of its proteins to adapt to
changes in physiological circumstances. Decrease of deamida-
tion rates to values below those in Tris summarized in Table 2,
however, would be difficult except in specialized structures.
Deamidation has been observed in the proteins of many other
organisms, too; thus, similar findings may be expected.
In summary, reliable and experimentally verified predictive
calculations of the deamidation rates of 1,371 Asn residues in a
representative collection of 126 human proteins have been
carried out. The results of these calculations show that deami-
dation of human proteins under physiological conditions is so
extensive that it is probably of pervasive and fundamental
biological importance. Otherwise, the genetic code would spec-
ify stable Asn configurations. Likely uses of deamidation include
the timing of biological processes and the postsynthetic produc-
tion of uniquely useful proteins.
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Table 2. Percentages of human proteins in Table 1 computed to be more than one-tenth or
one-half singly deamidated in Tris or phosphate buffer after 1, 5, 10, and 50 days
Days at 37°C
pH 7.4
Proteins singly deamidated by .1y10 Proteins singly deamidated by .1y2
Tris Phosphate Tris Phosphate
1 10% 13% 1.6% 4%
5 31% 43% 8% 13%
10 43% 56% 13% 20%
50 71% 82% 37% 49%
A phosphate buffer correction of (2)(computed Tris rate) was applied to obtain the phosphate rate of each
protein. Percentages produced in physiological solutions may be even higher. Steady-state physiological per-
centages are lowered by protein turnover.
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